巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    ADMA Biologics

    ADMA
    2.260
    0.190
    7.94%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・ADMA Biologics - 延遲價格・最後更新於 29/09 12:00
    最高位
    2.445
    最低位
    2.240
    開市價
    --
    前收市價
    2.455
    成交量(千)
    183.74
    成交額(百萬)
    2.96
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    443.77
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    2.920 - 1.010
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    ADMA Biologics
    證券代碼
    ADMA.US
    所屬板塊
    Biotechnology
    公司業務
    ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
    發行量
    195920353
    公司總部
    465 State Route 17
    公司網址
    https://www.admabiologics.com
    公司電話
    +1 201 478-5552
    暫無內容

    關於

    ADMA Biologics(ADMA.US)所屬的行業板塊為Biotechnology。
    ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
    詳細公司背景可參考: https://www.admabiologics.com